258 related articles for article (PubMed ID: 26560845)
1. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
Mok CC; Tsai WC; Chen DY; Wei JC
Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
[TBL] [Abstract][Full Text] [Related]
2. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.
Prado MS; Bendtzen K; Andrade LEC
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):985-995. PubMed ID: 28772079
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
Timlin H; Bingham CO
Expert Opin Biol Ther; 2014 Jul; 14(7):893-904. PubMed ID: 24720727
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
5. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
6. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.
Garcês S; Antunes M; Benito-Garcia E; da Silva JC; Aarden L; Demengeot J
Ann Rheum Dis; 2014 Jun; 73(6):1138-43. PubMed ID: 23666932
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.
Maneiro JR; Salgado E; Gomez-Reino JJ
JAMA Intern Med; 2013 Aug; 173(15):1416-28. PubMed ID: 23797343
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF treatment in rheumatoid arthritis.
Geiler J; Buch M; McDermott MF
Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263
[TBL] [Abstract][Full Text] [Related]
9. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
10. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
[TBL] [Abstract][Full Text] [Related]
11. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
Bendtzen K
Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
[No Abstract] [Full Text] [Related]
12. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
13. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
Tarnowski M; Paradowska-Gorycka A; Dąbrowska-Zamojcin E; Czerewaty M; Słuczanowska-Głąbowska S; Pawlik A
Expert Opin Drug Metab Toxicol; 2016; 12(1):41-55. PubMed ID: 26609565
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.
van Schouwenburg PA; Rispens T; Wolbink GJ
Nat Rev Rheumatol; 2013 Mar; 9(3):164-72. PubMed ID: 23399692
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
Kalden JR; Schulze-Koops H
Nat Rev Rheumatol; 2017 Nov; 13(12):707-718. PubMed ID: 29158574
[TBL] [Abstract][Full Text] [Related]
16. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
Hernández MV; Sanmartí R; Cañete JD
Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
Gibbons LJ; Hyrich KL
BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
[TBL] [Abstract][Full Text] [Related]
18. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
20. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
